M&A Deal Summary

Aurora Acquires MedReleaf

On May 14, 2018, Aurora acquired life science company MedReleaf for 3.2B CAD

Acquisition Highlights
  • This is Aurora’s 4th transaction in the Life Science sector.
  • This is Aurora’s 0th largest (disclosed) transaction.
  • This is Aurora’s 6th transaction in Canada.
  • This is Aurora’s 3rd transaction in Ontario.

M&A Deal Summary
Date 2018-05-14
Target MedReleaf
Sector Life Science
Buyer(s) Aurora
Deal Type Add-on Acquisition
Deal Value 3.2B CAD
Advisor(s) Canaccord Genuity Corp. (Financial)
Stikeman Elliott
Davies Ward Phillips & Vineberg (Legal)

Target

MedReleaf

Markham, Ontario, Canada
MedReleaf Corp. is an R&D-driven company provides cannabis. Sourced from around the world and carefully cultivated in one of two state of the art ICH-GMP and ISO 9001 certified facilities in Ontario, the Company delivers a variety of premium products for the global medical market and is committed to serving the therapeutic needs of its medical patients and providing a compelling product assortment for the adult-use recreational consumer.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Aurora

Edmonton, Alberta, Canada
Category Company
Founded 2013
Sector Life Science
Employees1,073
Revenue 270M CAD (2023)
DESCRIPTION

Aurora is a Canadian company and licensed producer of artisanal medical marijuana pursuant to the Marihuana for Medical Purposes Regulations. Aurora was founded in 2013 and is based in Edmonton, Alberta.

DEAL STATS #
Overall 7 of 13
Sector (Life Science) 4 of 5
Type (Add-on Acquisition) 7 of 12
State (Ontario) 3 of 5
Country (Canada) 6 of 10
Year (2018) 2 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-01-24 CanniMed Therapeutics

Saskatoon, Saskatchewan, Canada

CanniMed Therapeutics is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 17 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-compliant production process and world class research and development platforms with a wide range of pharmaceutical-grade cannabis products. In addition, the Company has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications.

Buy CA$1.1B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-12-10 Farmacias Magistrales S.A.

Mexico

Farmacias Magistrales S.A. is an importer of raw materials containing THC, the active ingredient in marijuana. It will distribute medical cannabis products containing over 1 percent THC, apparently through health care professionals.

Buy -
Mergr

Product

Company

Legal